Biodentine as a pulpotomy medicament for primary molars: a retrospective chart review

This retrospective chart review study investigates the long-term clinical outcome of Biodentine® (Tricalcium silicate) as a medicament for pulpotomy in primary molars. Data in this retrospective study was collected from the dental records of all patients that had at least one primary molar receive pulpotomy treatment (CDT code: D3221) between 01 July 2012 and 01 July 2015. This data includes child’s age, medical history, dental history, dental radiographs, pulpotomy procedure details and follow-up clinical notes. Kaplan-Meier Estimate was used to measure the fraction of successful pulpotomy procedures for up to 24 months. A total of 1758 pulpotomy procedures were performed on 1032 patients in our institute in the three-year period and 21.4% of them (N = 376) had follow-up dental records that qualified for the study. Eleven teeth out of 376 teeth were excluded from the statistical analysis due to loss of/broken stainless steel crowns (3.1%). Seventeen pulpotomy failures were identified out of the remaining 365 procedures. The survival probablity of using Biodentine® as a pulpotomy medicament is 96.3% for 18-month follow-up and 95.4% for 24-month follow-up. Biodentine®, a tricalcium silicate formulation, used as a pulpotomy medicament demonstrates a high clinical success rate (95.4%) over a 24-month peroid in primary molars.

Biodentine®; Pulpotomy; Primary molars; Pulp therapy; Mineral trioxide aggregate

[1] Pulp therapy for primary and immature permanent teeth. Pediatric Dentistry Journal. 2018; 40: 343–351.

[2] Peng L, Ye L, Guo X, Tan H, Zhou X, Wang C, et al. Evaluation of formocresol versus ferric sulphate primary molar pulpotomy: a systematic review and meta-analysis. International Endodontic Journal. 2007; 40: 751–757.

[3] Lewis B. The obsolescence of formocresol. British Dental Journal. 2009; 207: 525–528.

[4] Ibricevic H, Al-Jame Q. Ferric sulphate and formocresol in pulpotomy of primary molars: long term follow-up study. European Archives of Paediatric Dentistry. 2003; 4: 28–32.

[5] Ansari G, Ranjpour M. Mineral trioxide aggregate and formocresol pulpotomy of primary teeth: a 2-year follow-up. International Endodontic Journal. 2010; 43: 413–418.

[6] Zurn D, Seale NS. Seale. Light-cured calcium hydroxide vs. formocresol in human primary molar pulpotomies: a randomized controlled trial. Pediatric Dentistry Journal. 2008; 30: 34–41.

[7] Odabaş ME, Bodur H, Barιş E, Demir C. Clinical, Radiographic, and Histopathologic Evaluation of Nd:YAG laser pulpotomy on human primary teeth. Journal of Endodontics. 2007; 33: 415–421.

[8] Ferreira CMA, Sassone LM, Gonçalves AS, de Carvalho JJ, Tomás-Catalá CJ, García-Bernal D, et al. Physicochemical, cytotoxicity and in vivo biocompatibility of a high-plasticity calcium-silicate based material. Scientific Reports. 2019; 9: 3933.

[9] Farrugia C, Baca P, Camilleri J, Arias Moliz MT. Antimicrobial activity of ProRoot MTA in contact with blood. Scientific Reports. 2017; 7: 41359.

[10] Kusum B, Rakesh K, Richa K. Clinical and radiographical evaluation of mineral trioxide aggregate, biodentine and propolis as pulpotomy medicaments in primary teeth. Restorative Dentistry & Endodontics. 2015; 40: 276–85.

[11] Smaïl-Faugeron V, Glenny AM, Courson F, Durieux P, Muller-Bolla M, Fron Chabouis H. Pulp treatment for extensive decay in primary teeth. Cochrane Database of Systematic Reviews. 2018; 5: CD003220.

[12] Asgary S, Shirvani A, Fazlyab M. MTA and ferric sulfate in pulpotomy outcomes of primary molars: a systematic review and meta-analysis. Journal of Clinical Pediatric Dentistry. 2014; 39: 1–8.

[13] About I. Biodentine: from biochemical and bioactive properties to clinical applications. Giornale Italiano di Endodonzia. 2016; 30: 81–88.

[14] Luo Z, Li D, Kohli MR, Yu Q, Kim S, He WX. Effect of Biodentine™ on the proliferation, migration and adhesion of human dental pulp stem cells. Journal of Dentistry. 2014; 42: 490–497.

[15] Malkondu Ö, Kazandağ MK, Kazazoğlu E. A review on biodentine, a contemporary dentine replacement and repair material. BioMed Research International. 2014; 2014: 160951.

[16] Dhar V, Marghalani AA, Crystal YO, Kumar A, Ritwik P, Tulunoglu O, et al. Use of vital pulp therapies in primary teeth with deep caries lesions. Pediatric Dentistry Journal. 2017; 39: 146–159.

[17] Bani M, Aktaş N, Çınar Ç, Odabaş ME. The clinical and radiographic success of primary molar pulpotomy using Biodentine™ and mineral trioxide aggregate: a 24-month randomized clinical trial. Pediatric Dentistry Journal. 2017; 39: 284–288.

[18] Kaur M, Singh H, Dhillon JS, Batra M, Saini M. MTA versus Biodentine: review of literature with a comparative analysis. Journal of Clinical and Diagnostic Research for doctors. 2017; 11: ZG01–ZG05.

[19] Çelik BN, Mutluay MS, Arıkan V, Sarı Ş. The evaluation of MTA and Biodentine as a pulpotomy materials for carious exposures in primary teeth. Clinical Oral Investigations. 2019; 23: 661–666.

[20] Jasani B, Musale P, Jasani B. Efficacy of Biodentine versus formocresol in pulpotomy of primary teeth: a systematic review and meta-analysis. Quintessence International. 2022; 53: 698–705.

[21] Shafaee H, Alirezaie M, Rangrazi A, Bardideh E. Comparison of the success rate of a bioactive dentin substitute with those of other root restoration materials in pulpotomy of primary teeth: systematic review and meta-analysis. The Journal of the American Dental Association. 2019; 150: 676–688.

[22] Stringhini Junior E, dos Santos MGC, Oliveira LB, Mercadé M. MTA and biodentine for primary teeth pulpotomy: a systematic review and meta-analysis of clinical trials. Clinical Oral Investigations. 2019; 23: 1967–1976.

[23] Cuadros-Fernández C, Lorente Rodríguez AI, Sáez-Martínez S, García-Binimelis J, About I, Mercadé M. Short-term treatment outcome of pulpotomies in primary molars using mineral trioxide aggregate and Biodentine: a randomized clinical trial. Clinical Oral Investigations. 2016; 20: 1639–1645.

[24] Mohammadi Z. Chlorhexidine gluconate, its properties and applications in endodontics. Iranian Endodontic Journal. 2008; 2: 113–125.

[25] Goel MK, Khanna P, Kishore J. Understanding survival analysis: Kaplan-Meier estimate. International Journal of Ayurveda Research. 2010; 1: 274–278.

[26] Dental growth and development. Pediatric Dentistry Journal. 2016; 38: 413.

[27] Agarwal SR, Bendgude VD, Kakodkar P. Evaluation of success rate of lesion sterilization and tissue repair compared to Vitapex in pulpally involved primary teeth: a systematic review. Journal of Conservative Dentistry. 2019; 22: 510–515.

[28] Chen X, Liu X, Zhong J. Clinical and radiographic evaluation of pulpectomy in primary teeth: a 18-months clinical randomized controlled trial. Head & Face Medicine. 2017; 13: 12.

[29] Taha NA, Abdelkhader SZ. Outcome of full pulpotomy using Biodentine in adult patients with symptoms indicative of irreversible pulpitis. International Endodontic Journal. 2018; 51: 819–828.

[30] Taha NA, Abdulkhader SZ. Full pulpotomy with Biodentine in symptomatic young permanent teeth with carious exposure. Journal of Endodontics. 2018; 44: 932–937.

[31] Pham CL, Kratunova E, Marion I, da Fonseca MA, Alapati SB. Effect of overlying material on final setting of Biodentine ® in primary molar pulpotomies. Pediatric Dentistry Journal. 2019; 41: 140–145.

[32] Coll JA, Seale NS, Vargas K, Marghalani AA, Al Shamali S, Graham L, et al. Primary tooth vital pulp therapy: a systematic review and meta-analysis. Pediatric Dentistry Journal. 2017; 39: 16–123.